Related Experiment Videos
Breast-conserving therapy for stage I-II synchronous bilateral breast carcinoma
S V Gollamudi1, R S Gelman, G Peiro
1Department of Radiation Oncology, Harvard Medical School, Boston, Massachusetts, USA.
Cancer
|April 1, 1997
Summary
Early-stage synchronous bilateral breast carcinoma (SBBC) can be safely treated with bilateral breast-conserving therapy (BCT). This approach offers outcomes comparable to unilateral breast cancer treatment.
Area of Science:
- Oncology
- Surgical Oncology
- Breast Cancer Research
Background:
- Synchronous bilateral breast carcinoma (SBBC) is rare, with established management protocols lacking.
- Optimal treatment strategies for early-stage SBBC require further investigation.
Purpose of the Study:
- To evaluate the safety and efficacy of bilateral breast-conserving therapy (BCT) for early-stage SBBC.
- To compare outcomes of SBBC patients treated with BCT to those with unilateral breast carcinoma.
Main Methods:
- Retrospective review of 24 patients with clinical Stage I-II SBBC treated with bilateral BCT (1977-1989).
- SBBC defined as bilateral invasive carcinomas diagnosed within 1 month.
- Comparison with 1314 patients with unilateral Stage I-II breast carcinoma.
Main Results:
- No significant differences in disease-free survival (5-year: 70% vs. 74%) or overall survival (5-year: 88% vs. 87%) between SBBC and unilateral groups.
- Cosmetic outcomes were comparable, with excellent/good physician assessment in 100% of SBBC patients.
- Long-term complications were infrequent in both groups.
Conclusions:
- Bilateral BCT is a safe and effective treatment for carefully selected early-stage SBBC patients.
- Outcomes for early-stage SBBC treated with BCT are comparable to those with unilateral breast carcinoma.